Monotherapies presumably have limited long-term efficacy in terms of preventing adaptive resistance since (1) tumors with minor fractions of cancer cells that harbor non-G12C KRAS mutations will ultimately relapse due to selection of these subclones [113,114] and (2) several mechanisms have been proposed for how cancer cells can lose their KRAS dependency. This evidence concerns the gene KRAS and cancer.